Volume 29, Issue 3
DOI: 10.24205/03276716.2020.749
Clinical Efficacy Study of Edaravone on the Treatment of Severe Acute Cerebral Infarction
Abstract
Background: Nowadays, cerebral infarction is becoming a more and more frequentlyoccurring disease in clinical practice, it is characterized by acute onset and rapid disease progression in clinical practice, the high disability rate and mortality of this kind of disease highlights the significance of the treatment. Edaravone, which is newly developed and considered as a free radical scavenger, has a significant protective effect on neurons.
Objective: To study the efficacy of Edaravone in clinical on the treatment of severe acute cerebral infarction.
Method: Patients (n = 62) with severe acute cerebral infarction and received treatment in our department from February 2015 to August 2017 were included. They were divided into a treatment group and a control group, conventional treatment like intracranial pressure drop, water-electrolyte imbalance correction, intravenous thrombolysis therapy was used for the control group; Edaravone was given to the treatment group on the basis of the treatment for the control group. The clinical efficacy, the incidence of adverse reactions, ADL score and NIHSS score before and after treatment were compared and observed between the two groups.
Result: The total effective rate in treatment group was obviously higher compared with that of the control group (P < 0.05); but no difference in NIHSS and ADL score was found before treatment (P > 0.05), while the NIHSS and ADL score of treatment group were higher (P < 0.05) compared with that of reference group after the treatment.
Conclusion: Edaravone was effective on the of patients with severe acute cerebral infarction, which significantly improved the clinical symptoms, the condition and daily living quality of patients with neurological deficit, it is worthy of clinical application and promotion.
Keywords
Acute Cerebral Infarction, daily living scale, ADL